The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...